Shana Kelley

And it took us many years to get there.

But now turning this technology into our product, that's a whole other exercise.

I've run academic labs, but I've also run companies in the diagnostic space, startups that emerge from my labs.

I know the product development, roadmaps, the life cycles and all of this.

And that is really what we need to do next.

What we're doing right now is just making absolutely sure that we have a very robust prototype.

We are developing a prototype for human use so that we can

You know, when we start walking down that commercial path, we really know that we've got something robust in hand to start with.

That work will be done during 2026, and then we're ready to take that next step, either with a commercial partner, you know, the Avits, Dexcoms, you know, those players in the field, or, you know, we'll go it our own and

have a startup company that takes the next steps with it.

But I'm very committed to this.

I really believe in it, just in the way that you mentioned, that this really could be transformative for the way so many diseases are managed.

And so we absolutely want to see that through.

Will you let me do it?

Yeah, absolutely.

So the bio hubs are really unique types of biomedical research institutes.

They function in partnership with top tier world class research intensive universities.

In Chicago, we work with the University of Chicago, Northwestern, University of Illinois, Urbana-Champaign.

And we're really here to do high risk, high reward research to really be out in white space where there isn't a lot of activity in, let's say, the NIH funded parts of biomedical research.

And what I think is really cool about the model is that we bring together scientists, chemists, physicists,